Cytek Biosciences, Inc. (CTKB) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Cytek Biosciences, Inc.'s filing signal turned negative.

Cytek Biosciences, Inc. is a cell analysis solutions company that leverages its proprietary Full Spectrum Profiling (FSP) technology to provide advanced research and clinical tools. Its FSP technology utilizes a unique optical and electronic design to collect a full range of light emissions, enabling high-resolution, high-content, and high-sensitivity cell analysis with up to 50 biomarkers in a single sample. The company offers a suite of instruments, including the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, as well as the Aurora CS cell sorter, supported by proprietary SpectroFlo software, reagents, and services. In addition to its FSP platform, Cytek offers conventional and imaging flow cytometry instruments through its Amnis and Guava brands, acquired in February 2023. Cytek's solutions are utilized by pharmaceutical companies, biopharma companies, academic research centers, and contract research organizations globally, with a significant number of peer-reviewed publications validating its technology.

Revenue is primarily driven by the sale of its FSP instrument systems, accessories, and consumables, as well as service revenue from post-warranty contracts, installations, and repairs.